Patent US4155993A successfully refreshed from Google Patents.
US4155993A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Prolonged-release pharmaceutical compositions for oral administration, their methods of making and use
Assignee: Merck Sante SAS
•
Filing: 1978-01-13
•
Granted: 1979-05-22
•
Expires: 1998-01-13
Abstract
Abstract An orally administrable pharmaceutical composition comprises a dosage of the acid oralate of naftidrofuryl having a prolonged release coating which is a film formed from hydroxypropyl methyl cellulose and ethyl cellulose, the content of ethyl cellulose being between 30 and 50% and containing 8 to 15% of propylene glycol relative to the total of the cellulose derivatives. The composition, having prolonged therapeutic activity is capable of being used in the treatment of arterial diseases in limbs, circulatory disorders in the hands and feet, cerebral vascular disorders and diffuse circulatory insufficiency with elderly people.
Inventors
- 👤 Maryse Belleville
- 👤 Francoise Merle
- 👤 Jean-Claude Lechevin
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 11:14
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/20; A61K9/28; A61K9/2806; A61K9/2833; A61K9/286; A61K9/2866; A61K31/00; A61K31/33; A61K31/335; A61K31/34
Claims Analysis
Total Claims: 4
Claim 1
Independent Claim
101 words
An orally-administrable prolonged-release compressed tablet pharmaceutical composition, comprising, as an essential active ingredient, the acid oxalate of 3-(1-naphthyl)-2-tetrahydrofurfurylpropionic acid 2-(diethylamino)-ethyl ester and a prolonged release coating consisting of a film composed of hydroxypropylmethylcellulose and ethyl cellulose, the ethyl cellulose content being in the range of from 30 to 50% by weight, and, as a plasticizer therefore, from 8 to 15 weight percent of propylene glycol, both percentages being based on the total weight of the hydroxypropylmethylcellulose and ethyl cellulose, the thickness of the coating film being such as to increase the weight of the dosage unit by from 1 to 2%.
Claim 2
Dependent Claim
101 words
An orally-administrable prolonged-release compressed tablet pharmaceutical composition, comprising, as an essential active ingredient, the acid oxalate of 3-(1-naphthyl)-2-tetrahydrofurfurylpropionic acid 2-(diethylamino)-ethyl ester and a prolonged release coating consisting of a film composed of hydroxypropylmethylcellulose and ethyl cellulose, the ethyl cellulose content being in the range of from 30 to 50% by weight, and, as a plasticizer therefore, from 8 to 15 weight percent of propylene glycol, both percentages being based on the total weight of the hydroxypropylmethylcellulose and ethyl cellulose, the thickness of the coating film being such as to increase the weight of the dosage unit by from 1 to 2%.
Claim 3
Dependent Claim
31 words
A composition as claimed in claim 1, wherein the ethyl cellulose content is from 35 to 45% by weight and the propylene glycol content is from 8 to 10% by weight.
Claim 4
Dependent Claim
31 words
A composition as claimed in claim 1, wherein the ethyl cellulose content is from 43 to 45% by weight and the propylene glycol content is from 8 to 10% by weight.
References Cited (Backward Citations)
US2887440A
Cited
FR1290661A
Cited
GB978265A
Cited
US3247066A
Cited
US3334096A
Cited
US3388041A
Cited
US3538214A
Cited
US3835221A
Cited
US3917813A
Cited
US4083949A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1982-05-21 | 1982-11-20 | 1983-05-22 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1986-05-21 | 1986-11-20 | 1987-05-22 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1990-05-21 | 1990-11-20 | 1991-05-22 | $7700.00 | Window Closed / Lapsed |